Outlook Therapeutics (OTLK) Projected to Post Earnings on Wednesday

Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) will likely be announcing its earnings results before the market opens on Wednesday, February 12th. Analysts expect the company to announce earnings of ($0.85) per share for the quarter.

Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) last issued its quarterly earnings data on Friday, December 27th. The company reported ($0.77) earnings per share for the quarter, beating analysts' consensus estimates of ($0.83) by $0.06. On average, analysts expect Outlook Therapeutics to post $-2 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Outlook Therapeutics Stock Up 5.7 %

Shares of Outlook Therapeutics stock traded up $0.10 on Thursday, hitting $1.84. 406,018 shares of the company's stock traded hands, compared to its average volume of 883,411. Outlook Therapeutics has a 52-week low of $0.87 and a 52-week high of $12.85. The stock has a market cap of $58.84 million, a P/E ratio of -0.21 and a beta of 0.58. The firm's 50-day moving average is $1.86 and its 200 day moving average is $4.56.

Analysts Set New Price Targets

Several research analysts have weighed in on OTLK shares. Guggenheim reissued a "buy" rating and set a $12.00 price objective on shares of Outlook Therapeutics in a report on Friday, January 17th. HC Wainwright reiterated a "buy" rating and issued a $30.00 price target on shares of Outlook Therapeutics in a research note on Friday, January 17th. Chardan Capital restated a "neutral" rating on shares of Outlook Therapeutics in a research note on Monday, December 2nd. Finally, BTIG Research reduced their target price on Outlook Therapeutics from $50.00 to $9.00 and set a "buy" rating on the stock in a report on Friday, November 29th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $27.40.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.